Dispatches from Orrick's HealthTech Summit | Life Sciences Snapshot Q3 2026

U.S. life sciences venture activity has shifted decisively in 2026. After four consecutive years of declining deal volumes, the sector has entered a new phase. Through Q2 2026, investors have deployed $14.9 billion across 633 deals, with capital invested nearly tripling relative to reported figures in the previous edition. That acceleration reflects a market that has moved past hesitation and into execution.

Read Orrick’s Q3 2026 Life Sciences Snapshot for insights on these trends, and what this means for founders looking to access capital and advance innovation. This issue includes a roundtable focused on “Longevity and AgeTech”, a follow-on to an Orrick-hosted panel discussion held June 3 in New York City at the Orrick HealthTech Summit during New York Tech Week.

Read the report (30 minute read)

Contact Us